Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HISLE
ADC Name
h1F6-17 MMAE DAR4
Synonyms
h1F6-17-MMAE-DAR4
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Investigative
Indication
In total 2 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
Vorsetuzumab
  Antibody Info 
Antigen Name
CD70 antigen (CD70)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Asn-AlaGlu-Dpr-MDpr
  Linker Info 
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 40.21
%
786-O cells
Renal cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 40.21% (Day 25) Positive CD70 expression (CD70+++/++)
Method Description
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
In Vivo Model 786-O CDX model
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
References
Ref 1 Hydrophilic antibody-drug conjugates; 2015-08-20.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.